Neuropeptide Y (NPY)-expressing hippocampal interneurons represent a major population of GABAergic inhibitory neurons that play critical roles in regulating hippocampal circuit function, network oscillations, and memory processes[1]. These cells co-express somatostatin (SST) and are primarily located in the stratum oriens of CA1-CA3 and the hilus of the dentate gyrus. In Alzheimer's disease (AD), NPY-expressing interneurons undergo significant alterations that contribute to circuit dysfunction and memory impairment[2].
NPY+ hippocampal interneurons are characterized by:
| Marker | Expression | Function |
|---|---|---|
| NPY | Primary | Neuropeptide transmitter/modulator |
| SST | High co-expression | Co-released inhibitory peptide |
| NOS | Variable | Nitric oxide synthesis |
| Reelin | Variable | Extracellular matrix modulation |
| Y1R | High | G-protein coupled receptor |
| Y2R | High | Autoreceptor regulation |
NPY exerts its effects through multiple receptor subtypes in the hippocampus[3]:
Y1R activation increases neuronal excitability, while Y2R serves as an autoreceptor limiting NPY release[4].
NPY+ interneurons are strategically positioned in hippocampal layers:
These interneurons form specific synaptic connections:
NPY+ hippocampal interneurons exhibit distinct firing properties[5]:
The electrophysiological profile varies based on the precise subpopulation and hippocampal subfield.
NPY+ interneurons provide critical feedforward inhibition[6]:
These cells also mediate feedback inhibition:
NPY+ interneurons contribute to hippocampal oscillations[7]:
NPY directly affects synaptic plasticity and memory:
The NPY system undergoes significant changes in AD[8]:
| Change | Mechanism | Functional Impact |
|---|---|---|
| NPY levels increased | Compensatory response | Partial rescue of memory |
| Y1R downregulated | Receptor internalization | Reduced plasticity |
| Y2R upregulation | Autoreceptor activation | Decreased transmission |
| NPY+ neuron loss | Tau pathology | Network dysfunction |
Tauopathy specifically affects NPY+ interneurons[9]:
Upregulated NPY expression in AD may represent a compensatory mechanism:
Targeting the NPY system offers therapeutic potential[10]:
Key techniques for studying NPY+ interneurons:
The NPY receptor family consists of Y1, Y2, Y4, and Y5 receptors in the hippocampus. Each receptor subtype activates distinct intracellular signaling pathways:
Y1 Receptor (Y1R) Signaling:
Y2 Receptor (Y2R) Signaling:
Y5 Receptor (Y5R) Signaling:
NPY is released from both synaptic vesicles and dense-core granules:
The peptide modulates synaptic plasticity through:
NPY+ interneurons integrate multiple neurotransmitter signals:
| Transmitter | Effect on NPY+ Neurons | Interaction |
|---|---|---|
| Glutamate | Excitation via NMDA/AMPA | Feedforward inhibition |
| GABA | Inhibition via GABAB | Feedback control |
| Acetylcholine | Excitation via M1/M3 | Memory modulation |
| Serotonin | Modulation via 5-HT1/2 | Mood-state dependent |
NPY+ interneurons in the dentate-CA3 circuit provide critical modulation:
This creates a gating mechanism that:
Within the CA3 recurrent network:
In CA1, NPY+ interneurons:
Cerebrospinal fluid NPY levels show promise as:
PET ligands for NPY receptors under development:
Current drug development focuses on:
Y1R-Targeted Therapies:
Y2R-Targeted Therapies:
NPY Analogues:
Viral vector delivery of NPY:
Transplantation approaches:
| Line | Application |
|---|---|
| NPY-Cre | Targeting, optogenetics |
| NPY-GFP | Visualization |
| NPY-tdTomato | Lineage tracing |
| NPY-Cre;Rosa26-tdT | Circuit mapping |
Martin B, et al. Neuropeptide Y: An evolutionary conserved neuromodulator. 2007. ↩︎
De Pril R, et al. NPY expression in the aging brain. 2004. ↩︎
Colmers WF, et al. NPY Y1 receptor signaling in hippocampus. 2004. ↩︎
Stanley EM, et al. NPY Y2 receptor regulation of synaptic plasticity. 2016. ↩︎
Crozier RA, et al. NPY Y1 receptors in hippocampal interneurons. 2017. ↩︎
Carroll J, et al. NPY and memory: hippocampal role in learning and retrieval. 2011. ↩︎
Hu H, et al. NPY-induced modulation of hippocampal gamma oscillations. 2011. ↩︎
Song J, et al. NPY system alterations in Alzheimer's disease. 2019. ↩︎
Ribeiro AC, et al. NPY interneuron dysfunction in tauopathy. 2020. ↩︎
Yang J, et al. NPY as therapeutic target in neurodegeneration. 2018. ↩︎
Schmidt HL, et al. NPY rescues hippocampal interneuron function in aging. 2015. ↩︎